Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer

TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endo...

Full description

Bibliographic Details
Main Authors: Herr, Ingrid, Groth, Ariane, Salnikov, Alexei V., Büchler, Markus W., Moldenhauer, Gerhard
Format: Online
Language:English
Published: Landes Bioscience 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429579/
id pubmed-3429579
recordtype oai_dc
spelling pubmed-34295792012-08-29 Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer Herr, Ingrid Groth, Ariane Salnikov, Alexei V. Büchler, Markus W. Moldenhauer, Gerhard Author's View TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy. Landes Bioscience 2012-08-01 /pmc/articles/PMC3429579/ /pubmed/22934267 http://dx.doi.org/10.4161/onci.19532 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Herr, Ingrid
Groth, Ariane
Salnikov, Alexei V.
Büchler, Markus W.
Moldenhauer, Gerhard
spellingShingle Herr, Ingrid
Groth, Ariane
Salnikov, Alexei V.
Büchler, Markus W.
Moldenhauer, Gerhard
Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
author_facet Herr, Ingrid
Groth, Ariane
Salnikov, Alexei V.
Büchler, Markus W.
Moldenhauer, Gerhard
author_sort Herr, Ingrid
title Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_short Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_full Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_fullStr Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_full_unstemmed Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
title_sort combining forces to hit cancer stem cells: trail-lymphocytes and epcamxcd3 bispecific antibody show efficacy against pancreatic cancer
description TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
publisher Landes Bioscience
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429579/
_version_ 1611552746315448320

Similar Items